文献速递消化系统肿瘤

S-1对比卡培他滨一线治疗转移性结直肠癌的随机III期试验:荷兰结直肠癌协作组SALTO研究

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
PubMed 文献 · Ann Oncol · 2017-01-01

SALTO研究将161例未经治疗的转移性结直肠癌患者随机分入卡培他滨组或S-1组,比较手足综合征发生率。医生评估的任意级别手足综合征发生率卡培他滨组为73%、S-1组为45%(OR 0.31,95%CI 0.16-0.60,P=0.0005),3级手足综合征分别为21%和4%(P=0.003),疗效无显著差异。

要点

  • S-1组医生评估的任意级别手足综合征发生率为45%,卡培他滨组为73%(P=0.0005)。
  • S-1组3级手足综合征发生率为4%,卡培他滨组为21%(P=0.003)。
  • 两组中位无进展生存期、缓解率和总生存率无统计学显著差异。

核心结论

  • 在西方转移性结直肠癌患者中,S-1治疗与卡培他滨相比手足综合征发生率显著更低,且疗效相当。

研究设计与样本

  • 随机III期试验,纳入既往未治疗的转移性结直肠癌且计划接受氟尿嘧啶单药化疗的患者,1:1随机分组。
  • 卡培他滨组给药方案为卡培他滨1250 mg/m2口服(<70岁患者)或1000 mg/m2(≥70岁患者),每日两次,第1-14天。
  • S-1组给药方案为S-1 30 mg/m2口服,每日两次,第1-14天,每3周一个周期。
  • 两组均可选择联合贝伐珠单抗,共161例患者在27个中心随机。

主要发现

  • 医生评估的任意级别手足综合征发生率卡培他滨组为73%(n=80)、S-1组为45%(n=80),OR 0.31(95%CI 0.16-0.60),P=0.0005。
  • 3级手足综合征发生率卡培他滨组为21%、S-1组为4%(P=0.003)。
  • 患者自评任意级别手足综合征发生率卡培他滨组为84%、S-1组为58%(P=0.004)。
  • 3级厌食在S-1组更常见(卡培他滨组3% vs S-1组13%,P=0.03)。
  • 中位相对剂量强度卡培他滨组为88%、S-1组为95%(P=0.026);中位无进展生存期、缓解率和总生存率无统计学显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hand-foot syndrome (HFS) is a common side-effect of capecitabine. S-1 is an oral fluoropyrimidine with comparable efficacy to capecitabine in gastrointestinal cancers but associated with a lower incidence of HFS in Asian patients. This study compares the incidence of HFS between S-1 and capecitabine as first-line treatment in Western metastatic colorectal cancer (mCRC) patients. PATIENTS AND METHODS: Patients with previously untreated mCRC and planned treatment with fluoropyrimidine monochemotherapy were randomized 1 : 1 to receive either capecitabine (1250 mg/m2 orally for patients <70 years; 1000 mg/m2 for patients ≥70 years, twice daily on days 1-14) or S-1 (30 mg/m2 orally twice daily on days 1-14) in 3-weekly cycles, with bevacizumab optional in both groups. The primary endpoint was the incidence of any grade HFS, as assessed by both physicians and patients (diaries). Secondary endpoints included grade 3 HFS, other toxicities, relative dose intensity, progression-free survival, response rate and overall survival. RESULTS: A total of 161 patients were randomized in 27 centres. The incidence of any grade HFS as assessed by physicians was 73% in the capecitabine group (n = 80) and 45% in the S-1 group (n = 80) [odds ratio (95% confidence interval) 0.31 (0.16-0.60), P = 0.0005]. The incidence of grade 3 HFS was 21% and 4% (P = 0.003), respectively. Patient-assessed any grade HFS was 84% and 58%, respectively (P = 0.004). Grade 3 anorexia was more common in the S-1 group (3% versus 13%, P = 0.03). Median relative dose intensity was 88% in the capecitabine group and 95% in the S-1 group (P = 0.026). There were no statistically significant differences in median progression-free survival, response rate and overall survival rates. CONCLUSION: Treatment with S-1 in Western mCRC patients is associated with a significantly lower incidence of HFS compared with capecitabine, with comparable efficacy. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT01918852.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol. 2017. PMID: 28383633. doi:10.1093/annonc/mdx122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。